Anti-Neoplastic Therapy Market: By Agent Type (Alkylating and Alkylating-Like Agents, Antimetabolites, Antitumor Antibiotics, Plant Alkaloids, Hormonal Agents, and Miscellaneous Agents) By Product Type (Chemotherapeutic Agents, Immunotherapeutic Agents, and Personalized Medicine), By Cancer Type (Bladder Cancer, Prostate Cancer, Blood Cancer, Melanoma, Breast Cancer, Throat Cancer, Kidney Cancer, Uterine Cancer, Lungs Cancer, and Other), By End Users (Hospitals, Clinics, Research Institutes, Cancer Rehabilitation Centers, and Others) And Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Anti-Neoplastic Therapy Market size is expected to be valued at USD 134 billion in 2022 which is expected to grow at a CAGR of 7.8% from 2023-2029. Anti-neoplastic therapy is defined as a process that is used to cure infection imposed by neoplastic diseases such as malignant or benign tumors by using various types of modern medications and treatments such as cytotoxic drugs, oncology drugs, anticancer drugs, and immunotherapies. Neoplasms are tumor cells that grow indefinitely and cause neoplastic disease. One of the major causes of such types of diseases is changes in the DNA strand of the patient that leads to altered function of genes and eventually, cause some type of cancer. Rising research in the biotechnology and pharmaceutical domains for the discovery of new drugs can lead to the growth of the anti-neoplastic therapy market. Moreover, the high prevalence of cancer disease, technological advancements in drug development, and discoveries are some primary factors that can boost the global anti-neoplastic therapy market. Apart from these, various government interventions, high frequencies of cardiac attacks, and technological progress towards the improvement of human healthcare also accelerate the market in the future. However, some factors such as the absence of skilled professionals and the high cost of treatment can restrain the growth of the market. Increasing innovation in the sector of personalized medicines, and government affords to encourage control and prevention practices have created an opportunity for the growth of the global anti-neoplastic therapy market. Moreover, the competitive landscape and rising development in anti-neoplastic therapy are expected to produce lucrative opportunities for the global market share.

Anti-Neoplastic Therapy Market Key Developments:

  • In November 2021, LYT-200, a clinical therapeutic human IgG4 monoclonal antibody used for the treatment of pancreatic cancer developed by PureTech was approved by FDA as an Orphan Drug
  • In October 2021, Astra-tine-11, a gold nanoparticle utilizing system used for targeted cancer radiations, was developed by scientists of a Japanese University

Anti Neoplastic Therapy Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.8%

Largest Market

Asia-Pacific

Fastest Growing Market

North America
Anti-Neoplastic Therapy Market Dynamics

One of the major reasons for the growth of the global anti-neoplastic therapy market is the increasing prevalence of cancer among the population. The increasing cases of neoplasm around the world, and the constant demand for low-cost medications to treat them has increased the anti-neoplastic therapy market share. Various factors such as an increase in the geriatric population, and changing lifestyles of the people have increased the rate of cancer cases rapidly around the world. As the number of cancer cases is rising day by day, investment in cancer research by multinational companies has also increased simultaneously which can propel the growth of the market in the forecast years. Thus, the increasing rate of cancer cases and demand for inexpensive treatment can drive the market growth.

Anti Neoplastic Therapy Market Segmentation

By Product Type
  • Chemotherapeutic Agents
  • Immunotherapeutic Agents
  • Personalized Medicine
By Cancer Type
  • Bladder Cancer
  • Prostate Cancer
  • Blood Cancer
  • Melanoma
  • Breast Cancer
  • Throat Cancer
  • Kidney Cancer
  • Uterine Cancer
  • Lungs Cancer
  • Others
By End User
  • Hospitals
  • Clinics
  • Research Institutes
  • Cancer Rehabilitation Centers
  • Others

Frequently Asked Questions

The anti-neoplastic therapy market is projected to expand at a CAGR of 7.8% during the forecast period

AbbVie Inc., Pfizer Inc., Boehringer Ingelheim, Bayer AG, Eli Lilly and Company, Amgen Inc., Johnson and Johnson

North America is the fastest-growing region for anti-neoplastic therapy market

Key Features of the Reports

  • The anti-neoplastic therapy market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1. Executive Summary
2. Global Anti-Neoplastic Therapy Market Introduction
2.1. Global Anti-Neoplastic Therapy Market Taxonomy
2.2. Global Anti-Neoplastic Therapy Market Definitions
2.2.1. Product Type
2.2.2. Agent Type
2.2.3. Cancer Type
2.2.4. End User
2.2.5. By Region
3. Global Anti-Neoplastic Therapy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anti-Neoplastic Therapy Market Dynamic Factors - Impact Analysis
3.6. Global Anti-Neoplastic Therapy Market Competition Landscape
3.7. Epidemiology
4. Global Anti-Neoplastic Therapy Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Anti-Neoplastic Therapy Market, By Product Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1. Chemotherapeutic Agents
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunotherapeutic Agents
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Personalized Medicine
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Anti-Neoplastic Therapy Market, By Agent Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1. Alkylating and Alkylating-Like Agents
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Antimetabolites
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Antitumor Antibiotics
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Plant Alkaloids
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Hormonal Agents
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Miscellaneous Agents
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Anti-Neoplastic Therapy Market, By Cancer Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1. Bladder Cancer
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Prostate Cancer
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Blood Cancer
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Melanoma
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Breast Cancer
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Throat Cancer
7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Kidney Cancer
7.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Uterine Cancer
7.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
7.9. Lungs Cancer
7.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.9.3. Market Opportunity Analysis
7.10. Others
7.10.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.10.3. Market Opportunity Analysis
8. Global Anti-Neoplastic Therapy Market, By End User, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1. Hospitals
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Clinics
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Research Institutes
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Cancer Rehabilitation Centers
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Others
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9. Global Anti-Neoplastic Therapy Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Anti-Neoplastic Therapy Market - Opportunity Analysis Index, By Product Type, By Agent Type, By Cancer Type, By End User, and Region, 2023 - 2029
10. North America Anti-Neoplastic Therapy Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
10.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Chemotherapeutic Agents
10.1.2. Immunotherapeutic Agents
10.1.3. Personalized Medicine
10.2. Agent Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Alkylating and Alkylating-Like Agents
10.2.2. Antimetabolites
10.2.3. Antitumor Antibiotics
10.2.4. Plant Alkaloids
10.2.5. Hormonal Agents
10.2.6. Miscellaneous Agents
10.3. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Bladder Cancer
10.3.2. Prostate Cancer
10.3.3. Blood Cancer
10.3.4. Melanoma
10.3.5. Breast Cancer
10.3.6. Throat Cancer
10.3.7. Kidney Cancer
10.3.8. Uterine Cancer
10.3.9. Lungs Cancer
10.3.10. Others
10.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Research Institutes
10.4.4. Cancer Rehabilitation Centers
10.4.5. Others
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. USA
10.5.2. Canada
10.6. North America Anti-Neoplastic Therapy Market - Opportunity Analysis Index, By Product Type, By Agent Type, By Cancer Type, By End User, and Country, 2023 - 2029
10.7. North America Anti-Neoplastic Therapy Market Dynamics Trends
11. Europe Anti-Neoplastic Therapy Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
11.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Chemotherapeutic Agents
11.1.2. Immunotherapeutic Agents
11.1.3. Personalized Medicine
11.2. Agent Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Alkylating and Alkylating-Like Agents
11.2.2. Antimetabolites
11.2.3. Antitumor Antibiotics
11.2.4. Plant Alkaloids
11.2.5. Hormonal Agents
11.2.6. Miscellaneous Agents
11.3. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Bladder Cancer
11.3.2. Prostate Cancer
11.3.3. Blood Cancer
11.3.4. Melanoma
11.3.5. Breast Cancer
11.3.6. Throat Cancer
11.3.7. Kidney Cancer
11.3.8. Uterine Cancer
11.3.9. Lungs Cancer
11.3.10. Others
11.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Research Institutes
11.4.4. Cancer Rehabilitation Centers
11.4.5. Others
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Anti-Neoplastic Therapy Market - Opportunity Analysis Index, By Product Type, By Agent Type, By Cancer Type, By End User, and Country, 2023 - 2029
11.7. Europe Anti-Neoplastic Therapy Market Dynamics Trends
12. Asia-Pacific Anti-Neoplastic Therapy Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
12.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Chemotherapeutic Agents
12.1.2. Immunotherapeutic Agents
12.1.3. Personalized Medicine
12.2. Agent Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Alkylating and Alkylating-Like Agents
12.2.2. Antimetabolites
12.2.3. Antitumor Antibiotics
12.2.4. Plant Alkaloids
12.2.5. Hormonal Agents
12.2.6. Miscellaneous Agents
12.3. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Bladder Cancer
12.3.2. Prostate Cancer
12.3.3. Blood Cancer
12.3.4. Melanoma
12.3.5. Breast Cancer
12.3.6. Throat Cancer
12.3.7. Kidney Cancer
12.3.8. Uterine Cancer
12.3.9. Lungs Cancer
12.3.10. Others
12.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Research Institutes
12.4.4. Cancer Rehabilitation Centers
12.4.5. Others
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Anti-Neoplastic Therapy Market - Opportunity Analysis Index, By Product Type, By Agent Type, By Cancer Type, By End User, and Country, 2023 - 2029
12.7. Asia-Pacific Anti-Neoplastic Therapy Market Dynamics Trends
13. Latin America Anti-Neoplastic Therapy Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
13.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Chemotherapeutic Agents
13.1.2. Immunotherapeutic Agents
13.1.3. Personalized Medicine
13.2. Agent Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Alkylating and Alkylating-Like Agents
13.2.2. Antimetabolites
13.2.3. Antitumor Antibiotics
13.2.4. Plant Alkaloids
13.2.5. Hormonal Agents
13.2.6. Miscellaneous Agents
13.3. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Bladder Cancer
13.3.2. Prostate Cancer
13.3.3. Blood Cancer
13.3.4. Melanoma
13.3.5. Breast Cancer
13.3.6. Throat Cancer
13.3.7. Kidney Cancer
13.3.8. Uterine Cancer
13.3.9. Lungs Cancer
13.3.10. Others
13.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Research Institutes
13.4.4. Cancer Rehabilitation Centers
13.4.5. Others
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Anti-Neoplastic Therapy Market - Opportunity Analysis Index, By Product Type, By Agent Type, By Cancer Type, By End User, and Country, 2023 - 2029
13.7. Latin America Anti-Neoplastic Therapy Market Dynamics Trends
14. Middle East and Africa Anti-Neoplastic Therapy Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
14.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Chemotherapeutic Agents
14.1.2. Immunotherapeutic Agents
14.1.3. Personalized Medicine
14.2. Agent Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.2.1. Alkylating and Alkylating-Like Agents
14.2.2. Antimetabolites
14.2.3. Antitumor Antibiotics
14.2.4. Plant Alkaloids
14.2.5. Hormonal Agents
14.2.6. Miscellaneous Agents
14.3. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Bladder Cancer
14.3.2. Prostate Cancer
14.3.3. Blood Cancer
14.3.4. Melanoma
14.3.5. Breast Cancer
14.3.6. Throat Cancer
14.3.7. Kidney Cancer
14.3.8. Uterine Cancer
14.3.9. Lungs Cancer
14.3.10. Others
14.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Research Institutes
14.4.4. Cancer Rehabilitation Centers
14.4.5. Others
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. MEA Anti-Neoplastic Therapy Market- Opportunity Analysis Index, By Product Type, By Agent Type, By Cancer Type, By End User, and Country, 2023 - 2029
14.7. MEA Anti-Neoplastic Therapy Market Dynamics Trends
15. Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Key Product Types, Key Developments, Strategies, and SWOT Analysis)
15.2.1. AbbVie Inc.
15.2.2. Pfizer Inc.
15.2.3. Boehringer Ingelheim
15.2.4. Bayer AG
15.2.5. Eli Lilly and Company
15.2.6. Amgen Inc.
15.2.7. Johnson and Johnson
15.2.8. Merck and Co.
15.2.9. Teva Pharmaceutical Industries Ltd
15.2.10. AstraZeneca Inc
16. Research Methodology
17. Key Assumptions and Acronyms
  • AbbVie Inc.
  • Pfizer Inc.
  • Boehringer Ingelheim
  • Bayer AG
  • Eli Lilly and Company
  • Amgen Inc.
  • Johnson and Johnson
  • Merck and Co.
  • Teva Pharmaceutical Industries Ltd
  • AstraZeneca Inc.

Adjacent Markets